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Available online 30 May 2016AbstractBackground: Gastric gastrointestinal stromal tumors (GISTs) represent a subgroup of GISTs with a better prognosis than those located in
other areas. In this retrospective study we performed a molecular characterization of a large series of patients with gastric GISTs in relation
to clinicalepathological characteristics and prognosis.
Methods: DNAwas extracted from paraffin-embedded sections from 221 gastric GIST patients submitted to surgery. Exons 9, 11, 13 and 17
of KIT, exons 12 and 18 of PDGFRA and exons 11 and 15 of BRAF were analyzed by direct sequencing. Cox regression analysis adjusted
for clinicalepathological factors was performed to evaluate KIT and PDGFRA mutations in relation to the composite endpoint of relapse or
death.
Results: KIT and PDGFRA mutations were observed in 119 (53.8%) and 56 (25.3%) patients, respectively, whereas 46 (20.8%) patients had
wild type (wt) disease. Univariable analyses showed that a high Miettinen risk category and the presence of ulceration and KIT deletionshor. Tel.: þ39 0543 739277; fax: þ39 0543 739221.
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1207L. Capelli et al. / EJSO 42 (2016) 1206e1214were associated with increased risk of relapse or death (p < 0.001; p ¼ 0.0389 and p ¼ 0.002, respectively). After adjusting for Miettinen
risk score, KIT deletions remained an independent prognostic factor (HRadj ¼ 2.65, 95% CI [1.15e6.13], p ¼ 0.023). Moreover, KIT de-
letions in exon 11 codons 557, 558 or 559 were associated with a higher risk of relapse or death than wt tumors (HRadj ¼ 3.29 95% CI
[1.64e6.64], p ¼ 0.001).
Conclusions: KIT deletions in exon 11, especially those involving codons 557, 558 or 559, were correlated with a more aggressive gastric
GIST phenotype and increased risk of relapse or death.
 2016 Elsevier Ltd. All rights reserved.
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8Introduction
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the gastrointestinal tract
and can develop in any part of this area; 60e70% of clin-
ically manifest tumors arise in the stomach and 20e30%
in the small intestine, but a small percentage also occurs
in the rectum, colon, esophagus or omentum.1e3 About
70e80% of GISTs harbor a KIT gene mutation in exons
11 (about 60% of cases) and 9 (7e10%) and, less
frequently, in exons 13 and 17.4e6 About 20e30% of KIT
wild type (wt) GISTs show mutations in the platelet-
derived growth factor receptor alpha (PDGFRA) gene, in
particular in exons 12, 14 and 18,6,7 while a lower percent-
age (4e13%) have BRAF mutations.8e10
Gastric GISTs represent a subgroup of GISTs with a
favorable prognosis and are characterized by a relatively
higher fraction of cases with an epithelioid or mixed epithe-
lioid/spindle morphology, a higher frequency of PDGFRA
mutations and a lower frequency of KIT alterations, a lower
mitotic index and overall lower mortality than other
GISTs.11e14 Whilst the predictive role of KIT and PDGFRA
mutations in relation to response to imatinib is well
known,15e17 the prognostic significance of these mutations
and of the type of mutation has yet to be defined. Some
studies have shown that gastric GISTs with exon 11 dele-
tions have a worse outcome than those with single nucleo-
tide substitutions at the same exon.18e20 PDGFRA exon 18
mutations have also been associated with a lower risk of
metastasis and a better prognosis.12,18 Other studies have
demonstrated that, in addition to different exons, the type
of mutation and several codons affected by mutations
may have different prognostic implications. In particular,
KIT exon 11 deletions are associated with a risk of metas-
tasis, while those involving codons 557e558 indicate a
higher risk of progression.21e25 Conversely, single KIT
exon 11 substitutions have been correlated with longer
relapse-free and overall survival.15,21,23,25,26 Moreover,
KIT exon 9 duplications, which occur mainly in intestinal
tumors, have been associated with aggressive behavior.21,25
A number of studies have also analyzed BRAF gene al-
terations in GISTs, reporting a mutation frequency of about
4e13%.8e10 A predominant small intestinal location of
GISTs with BRAF V600E has been observed, followedby a location in the stomach. BRAF mutations are not
per se indicative of malignancy in that they have not
been found to show a significant correlation with prog-
nosis.9 However, a recent study in which GIST patients
were divided into 3 prognostic groups on the basis of
type of mutation found that BRAF mutations were associ-
ated with the group with the best prognosis, suggesting a
positive prognostic effect of this alteration.27
The main aim of our retrospective study was to assess
KIT, PDGFRA and BRAF mutations in a large series of pa-
tients with gastric GISTs recruited by member centers of
the Italian Research Group of Gastric Cancer (GIRCG).
We analyzed different gene mutations and types of muta-
tion in relation to the clinicalepathological characteristics
of patients to see whether this information could be used
to improve the clinical management of the disease.Materials and methodsCase seriesWe retrospectively analyzed a cohort of 221 patients
with gastric GISTs submitted to surgical resection be-
tween March 1985 and December 2012. All cases were re-
cruited from 8 member centers of the Italian Gastric
Cancer Research Group (GIRCG). Information on clini-
calepathological data such as tumor size, mitosis, pres-
ence of ulceration, necrosis, atypia and type of
cellularity was collected by reviewing all available medi-
cal and histopathological records archived in GIRCG cen-
ters. The study was approved by the Local Ethics
Committee of each center.
Histopathological variables analyzed for each tumor
were as follows: size, mitotic count per 50 high-power
fields (HPF), cell type, presence or absence of ulceration,
necrosis and nuclear atypia, and pattern of KIT and MIB1
immunostaining. Immunohistochemical staining was per-
formed using the following primary antibodies: KIT
(CD117 antigen, Dako Corporation, Carpenteria, CA,
USA) and Ki67 (MIB1, Dako Corporation).
On the basis of the Miettinen risk score, GISTs were
stratified as no-, very low-, low-, intermediate- and high-
risk tumors.2
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ples were used for molecular analysis. For each sample,
areas containing at least 50% of tumor cells were selected
in hematoxylin-eosin-stained sections, macrodissected in 5-
mM sections and collected in specific tubes for DNA extrac-
tion. Tumor cells were lysed overnight at 56 C in 50 mM
of KCl, 10 mM of TriseHCl pH 8.0, 2.5 mM of MgCl2 and
Tween-20 (0.45%) in the presence of 1.25 mg/ml of pro-
teinase K. Proteinase K was inactivated at 95 C for
10 min and samples were centrifuged twice at 6000 rpm
to eliminate debris. DNA quantity and quality were as-
sessed by Nanodrop (Celbio, Milan, Italy). Fifty nanograms
of DNA were used for PCR amplification.
KIT exons 9, 11, 13 and 17 and PDGFRA exons 12 and
18 were analyzed by direct sequencing using 3130 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
Primer sequences and localizations are reported in Table
S1 and Fig. S1, respectively.
BRAF exons 11 and 15 were analyzed by pyrosequenc-
ing using an anti-EGFR MoAb response (BRAF-status) kit
(Diatech, Jesi, Ancona, Italy), according to the manufac-
turer’s instructions. Reactions were run on a PyroMark
Q96 ID (Qiagen, Milan, Italy).Statistical analysisThe primary endpoint of the study was recurrence-free
survival (RFS), defined as the time from the date of surgery
to the date of tumor recurrence or death resulting from any
cause. In patients who did not relapse or died, the end date
was the last follow up. Descriptive statistics were reported
as frequencies and percentages for categorical variables and
as mean  standard deviation (SD) for continuous vari-
ables. The association between types of mutation and de-
mographic (age and gender) and clinicalepathological
features was assessed by the t-test and Chi-square test or
Fisher’s Exact test, as appropriate. Survival curves were
estimated using the KaplaneMeier method, while the sta-
tistical significance of the differences between curves was
assessed using the log-rank test. The prognostic impact of
specific variables on survival was analyzed by univariable
and multivariable Cox proportional hazards models. Results
are reported as Hazard Ratios (HRs) and 95% confidence
intervals (95% CI). The proportional hazards assumption
was checked by the Schoenfeld residuals-based test. For
some variables, levels were combined due to the low num-
ber of observations.
The choice of variables to include in the multiple Cox
regression model was based on stepwise selection methods
and careful clinical judgment. The Akaike Information Cri-
terion was used to select the final multiple regression
models. The two multivariable Cox regression models
included the Miettinen risk score as adjustment factor and
the different types of mutation or the exon 11 KITmutations. Statistical interactions between demographic,
clinicalepathological variables and type of mutation were
explored. The prognostic role of the type of mutation was
also assessed within treatment groups.
All statistical analyses were carried out using STATA
10.1 statistical software (StataCorp, College Station, TX,
USA). A two-sided p-value < 0.05 was deemed statistically
significant for all the analyses.
ResultsPatient characteristicsInformation available on the clinicalepathological char-
acteristics of the of 221 gastric GIST patients is reported in
Table 1. Mean age at the time of surgery was 65  13 years.
One hundred and twenty patients (54.3%) were male and
101 (45.7%) were female. One hundred and sixty-two
(85.7%) did not receive any type of treatment, 27
(14.3%) underwent neoadjuvant or adjuvant therapy and
no information about treatment was available for 32 pa-
tients. Treated patients were similar to non treated patients
as regards demographic variables but had a more serious
clinical and histological profile (Table S2). In particular,
they showed significantly higher tumor dimensions
(p ¼ 0.001) and number of mitoses (p < 0.001). Conse-
quently, the Miettinen risk score was substantially higher
in treated patients and necrosis and atypia were more
frequent, albeit not significantly, than in non treated cases
(p ¼ 0.091 and p ¼ 0.074, respectively).Genotype analysisOverall, 119 (53.8%) patients showed KIT mutations and
56 (25.3%) had PDGFRA mutations. Forty-six (20.8%) pa-
tients had KIT and PDGFRAwt GISTs. No BRAF mutations
were detected. One hundred and sixteen of the 119 KIT-
mutated patients showed alterations in exon 11:47 point
mutations, 43 deletions and 26 insertions. Three patients
had mutations in exon 9, all of which were insertions.
Five of the 56 PDGFRA-mutated patients had exon 12 al-
terations (4 point mutations and 1 deletion), while 51
showed exon 18 mutations (44 point mutations and 7
deletions).Association between mutations and
clinicalepathological characteristics of patientsThe associations between the different types of muta-
tions and pathologic tumor features are presented in Table
S3. The majority of KIT mutations displayed spindle
morphology, while PDGFRA alterations had a mainly
epithelioid phenotype (76.3% and 41.9%, respectively;
p < 0.001). In general, the majority of GISTs carrying
KIT or PDGFRA mutations had low mitotic activity (5/
50 HPF) (85.1% and 75.2% respectively; p ¼ 0.052).
Table 1
Clinical pathological characteristics of gastric GIST patients (n ¼ 221).
n (%)
Gender
Male 120 (54.3)
Female 101 (45.7)
Missing e
Age at diagnosis, years
Mean  SD 65.4  13.1
Range 20e91
Missing 5
Tumor dimension, cm
 2 43 (20.3)
3e5 74 (34.9)
6e10 64 (30.2)
> 10 31 (14.6)
Missing 9
Mitoses
5 143 (74.5)
>5 49 (25.5)
Missing 29
Ulceration
No 130 (83.9)
Yes 25 (16.1)
Missing 66
Necrosis
No 118 (74.2)
Yes 41 (25.8)
Missing 62
Atypia
No 126 (79.8)
Yes 32 (20.2)
Missing 63
Miettinen risk score
No risk 39 (18.6)
Very low 48 (22.9)
Low 49 (23.3)
Moderate 29 (13.8)
High 45 (21.4)
Missing 11
Cellularity
Mixed 36 (21.2)
Spindle 99 (58.2)
Epithelioid 35 (20.6)
Missing 51
Treatment
No 162 (85.7)
Adjuvant/neoadjuvant 27 (14.3)
Missing 32
SD e standard deviation.
Table 2
KIT and PDGFRA mutation distribution (n ¼ 190).
Type of mutation n (%)
wt KIT/PDGFRA 38 (20.0)
KIT 100 (52.6)
Exon 9: 3
Insertions 3 (1.6)
Exon 11: 97
Point mutations 36 (18.9)
Codons 557, 558 or 559 22
Deletions 40 (21.1)
Codons 557, 558 or 559 26
Insertions 21 (11.1)
Codon 557, 558 or 559 1
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features, i.e., a higher percentage of spindle cellularity
(p < 0.001), necrosis (p ¼ 0.045), and a higher Miettinen
risk score (p ¼ 0.004), (Table S3).PDGFRA 52 (27.4)
Exon 12 5Survival analyses
Point mutations 4 (2.1)
Deletions 1 (0.5)
Exon 18 47
Point 40 (21.1)
Deletions 7 (3.7)
wt e wild type.The relationship between mutations and patient prog-
nosis in terms of RFS (considered as a composite endpoint
including recurrence or death, whichever came first) was
evaluated in 190 patients for whom information on dateof surgery and follow up was available. Of these, 151
(79.5%) did not receive any type of treatment after surgery,
while 27 (14.2%) received adjuvant or neoadjuvant therapy.
Data were missing for 12 (6.3%) patients. The median
follow up of patients who remained relapse-free after the
last update was 72 months. There were 23 recurrences
and 34 deaths from all causes without previous relapse,
of which 19 from other tumors, 10 from non-cancer-
related disease, one from old age and 4 from unknown
causes. KIT mutations were detected in 100 (52.6%) of
the 190 patients, while PDGFRA alterations were observed
in 52 (27.4%) cases. Thirty-eight (20%) patients harbored
the wt form of either gene. Three (3%) KIT mutations
were exon 9 insertions, 40 (40%) were exon 11 deletions,
36 (36%) were exon 11 point mutations, and 21 (21%)
were exon 11 insertions. Mutations involving codons 557,
558 or 559 were observed in 49 (49%) KIT-mutated pa-
tients. In particular, codons 557, 558 or 559 were involved
in 22/36 (61%), 26/40 (65%) and 1/21 (5%) exon 11 point
mutations, deletions or insertions, respectively (Table 2).
Among PDGFRA mutations, 5 (10%) were at codon 12
(4 point mutations and 1 deletion) and 47 (90%) were at
codon 18 (40 point mutations and 7 deletions) (Table 2).
The association between mutation types and RFS is re-
ported in Fig. 1.
A significantly lower RFS was observed in patients with
KIT deletions than in those with KIT and PDGFRA wt,
PDGFRA-mutated, and KIT point or insertion mutations
(p ¼ 0.002) (Fig. 1A). Moreover, mutations in codons
557, 558 or 559, in particular deletions, were associated
with a significantly lower RFS than wt genes or mutations
in other codons (p < 0.001) (Fig. 1BeC).
Cox univariable analyses showed that tumor dimension,
number of mitoses, presence of ulceration, necrosis and a
high Miettinen risk score were associated with a higher
wt KIT/PDGFRA
PDGFRA
KIT point/insertion
KIT deletion
A)
0.
00
0.
25
0.
50
0.
75
1.
00
R
FS
0 10 20 30 40 50 60
Months after surgery
wt KIT/PDGFRA
KIT mutation in other codon
KIT mutation in codon 557/558/559
B)
0.
00
0.
25
0.
50
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1.
00
R
FS
0 10 20 30 40 50 60
Months after surgery
wt KIT/PDGFRA
Other KIT mutations
KIT deletion in codon 557/558/559
C)
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0.
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0.
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0.
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00
R
FS
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Months after surgery
Figure 1. Association between the type of KIT mutation, PDGFRA and recurrence-free survival (RFS-combined endpoint) after surgery. (A) GISTs with KIT
mutations, PDGFRA mutations or no mutations in either gene; (B) GISTs with KIT mutations in exon 11 codons 557 or 558 or 559, in other codons, or no
mutations in either gene; (C) GISTs with KIT deletions in exon 11 codons 557 or 558 or 559, other KIT mutations in exon 11, or KIT deletions in exon 11 in
codons other than 557, 558 or 559.
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[1.14e4.09], p ¼ 0.017, HR [95% CI] ¼ 3.98
[2.21e7.19], p < 0.001, HR [95% CI] ¼ 2.15
[1.04e4.41], p ¼ 0.038, HR [95% CI] ¼ 1.85
[0.99e3.43], p ¼ 0.053, HR [95% CI] ¼ 4.11
[2.43e6.95], p < 0.001) (Table 3). The treatment variable
was statistically significant with a HR [95% CI] of 3.97
[2.08e7.59] (p < 0.001). This apparently counterintuitive
result was mainly due to the fact that treated patients in
this retrospective study were characterized by a worse clin-
ical profile than non-treated patients (i.e., high Miettinen
risk score, >5 mitoses, larger tumors).
The presence of KIT mutations was associated with a
higher risk of recurrence or death (HR [95% CI] ¼ 2.21
[1.03e4.75], p ¼ 0.042). In particular, KIT deletions
were associated with a poorer prognosis than other alter-
ations (HR [95% CI] ¼ 3.65 [1.62e8.22], p ¼ 0.002)
(Table 3). With regard to the different codons involved, a
higher risk of relapse or death was observed in patients
with codons 557, 558 or 559 mutations compared to wtpatients or those who had mutations in other sites (HR
[95% CI] ¼ 3.68 [1.65e8.24], p ¼ 0.001) (Table 3). This
difference was even more evident in patients with deletions
involving codons 557, 558 or 559 (HR [95% CI] ¼ 5.52
[2.39e12.76], p < 0.001) (Table 3).
The results from two multivariable Cox regression
models are reported in Table 4. Model 1 considers the prog-
nostic effect of the type of mutations (KIT or PDGFRA) ad-
justing for the Miettinen risk score, while Model 2 focuses
on the effect of the different types of exon 11 KIT muta-
tions on prognosis, once again adjusting for the Miettinen
score. After adjusting, KIT deletions remained an indepen-
dent predictor of recurrence or death (HRadj [95%
CI] ¼ 2.65 [1.15e6.13], p ¼ 0.023) (Table 4 e Model
1), as did KIT deletions at codons 557, 558 or 559 (HRadj
[95% CI] ¼ 3.29 [1.64e6.64], p ¼ 0.001) (Table 4 e
Model 2). In the latter model we performed an adjusted
comparison between KIT deletions in the codons consid-
ered and other types of KIT mutations or KIT deletions in
other codons. The risk of recurrence or death for patients
Table 3
Results from univariable analysis using the Cox proportional hazards
model.
HR [95% CI] p
Gender
Female 1
Male 1.45 [0.85e2.47] 0.175
Age at diagnosis, years 1.02 [1.00e1.05] 0.049
Tumor dimension, cm
 5 1
6-10 1.21 [0.64e2.25] 0.558
>10 2.16 [1.14e4.09] 0.017
Mitoses
 5 1
>5 3.98 [2.21e7.19] <0.001
Ulceration
No 1
Yes 2.15 [1.04e4.41] 0.038
Necrosis
No 1
Yes 1.85 [0.99e3.43] 0.053
Atypia
No 1
Yes 1.65 [0.85e3.18] 0.135
Miettinen risk score
Low 1
High 4.11 [2.43e6.95] <0.001
Cellularity
Mixed 2.04 [0.77e5.38]
Spindle 1.41 [0.58e3.44] 0.149
Epithelioid 1 0.444
Treatment
No 1
Adjuvant/neoadjuvant 3.97 [2.08e7.59] <0.001
Gene mutations
wt KIT/PDGFRA 1
KIT 2.21 [1.03e4.75] 0.042
PDGFRA 1.06 [0.42e2.69] 0.904
Type of mutation [KIT/PDGFRA]
wt KIT/PDGFRA 1
KIT point/insertion 1.43 [0.61e3.34] 0.412
Deletion 3.65 [1.62e8.22] 0.002
PDGFRA 1.06 [0.42e2.70] 0.8974
Exon 11 KIT mutations
wt KIT/PDGFRA 1
In codons 557/558/559 3.68 [1.65e8.24] 0.001
Not in codons 557/558/559 1.12 [0.45e2.79] 0.811
Exon 11 KIT mutations
wt KIT/PDGFRA 1
KIT deletion in codons 557/558/559 5.52 [2.39e12.76] <0.001
KIT point/insertion or deletion
not in codons 557/558/559
1.33 [0.58e3.07] 0.504
wt e wild type.
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than 3-fold higher that of patients with other types of mu-
tations or mutations in other positions (HRadj [95%
CI] ¼ 3.17 [1.63e6.14], p ¼ 0.001) (results not shown).
Survival analysis revealed that the type of mutation only
influenced the non treated patient group (Table S4). In uni-
variable analysis, older age, higher number of mitoses, high
Miettinen score, and the presence of ulceration were signif-
icantly associated with an increased risk of relapse or deathin this group (results not shown). With regard to the molec-
ular variables, a KIT deletion was associated with an almost
4-fold increased risk of relapse or death compared to wt pa-
tients (HR [95% CI] ¼ 3.71 [1.19e11.62, p ¼ 0.024]).
Considering KIT deletions in codons 557, 558 or 559, the
risk was almost 6-fold higher than that of wt patients
(HR [95% CI] ¼ 5.81 [1.77e19.06, p ¼ 0.004]). After ad-
justing for the Miettinen score, the risk for KIT-deleted pa-
tients was 3-fold that of wt cases, but not significant (HRadj
[95% CI] ¼ 3.00 [0.92e9.75, p ¼ 0.068]) (Table S4, Model
1). KIT deletions in codons 557, 558 or 559 were signifi-
cantly associated with a poorer prognosis with respect to
wt tumors (HRadj [95% CI] ¼ 3.94 [1.12e13.81,
p ¼ 0.032]) (Table S4, Model 2). In treated patients, the
only variable associated with RFS was the Miettinen score
and none of the molecular variables proved significant even
after adjusting for the score (Table S5, Models 1 and 2).
Discussion
The prediction of clinical behavior and the prognosis of
patients with GISTs depend largely on classic clini-
calepathological risk criteria based on tumor size, mitotic
activity and localization of the primary lesion. The muta-
tional status of KIT and PDGFRA can predict the response
to treatment with tyrosine kinase inhibitors,16,17 but its role
as a prognostic factor remains unclear. Moreover, a signif-
icant association has been found between clinicalepatho-
logical parameters and molecular alterations, which could
also prove to be a prognostic factor.
In our retrospective case series of gastric GISTs, 53.9%
and 25.3% of patients showed KIT and PDGFRA mutations,
respectively, while 20.8% had KIT and PDGFRAwt tumors.
These frequencies are lower for KIT and higher for
PDGFRA than the same mutations observed in non gastric
GISTs,4,5,7,10,21,28 in agreement with results from other
studies. Miettinen et al.14 observed a 22.6% incidence of
PDGFRA mutations in a series of gastric GISTs, while Wa-
sag et al.29 reported that all PDGFRA mutations (25%)
found in their GIST case series were observed in gastric
GISTs. In Wardelmann et al.’s study,30 all the GISTs with
PDGFRA mutations (23%) were located in the stomach,
whereas tumors with KIT mutations (47%) or wt status
were also found in the small bowel.
It has been shown that PDGFRA mutations in GISTs are
associated with a better prognosis.7,15,18,21,31 The higher
PDGFRA mutation frequency observed in gastric GISTs
is in accordance with the better prognosis observed for
this type of tumor.12,30,32 Our study revealed the potential
prognostic relevance of the type and position of KIT muta-
tions in untreated resected gastric GISTs, in addition to
classic pathological criteria such as dimension, mitosis,
Miettinen risk stratification, ulceration and necrosis. Tu-
mors with mutations (especially deletions), affecting co-
dons 557, 558 or 559 of KIT exon 11 would appear to be
a distinct subset of gastric GISTs with malignant clinical
Table 4
Results from two multivariable Cox regression models.
Model 1 Model 2
HRadj [95% CI] p HRadj [95% CI] p
Type of mutation [KIT/PDGFRA]
wt KIT/PDGFRA 1
KIT point/insertion 0.99 [0.41e2.39] 0.977
KIT deletion 2.65 [1.15e6.13] 0.023
PDGFRA 1.06 [0.42e2.69] 0.906
Miettinen risk score
Low 1 1
High 3.36 [1.90e5.93] <0.001 3.12 [1.75e5.55] <0.001
Exon 11 KIT mutations
wt KIT 1
KIT deletion in codons 557/558/559 3.29 [1.64e6.64] 0.001
KIT point mutation/insertion or deletion not in codons 557/558/559 1.04 [0.53e2.03] 0.909
wt e wild type.
HRadj e adjusted hazard ratio.
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associated with a higher risk of relapse or death than that of
deletions with no involvement of any of these codons.
Moreover, survival analysis showed that patients with these
mutations had a lower RFS than those with mutations in
other sites. Multiple regression analysis confirmed the inde-
pendent prognostic value of this finding: adjusting for the
clinical covariate of the Miettinen risk stratification system,
deletions of exon 11 codons 557, 558 or 559 remained an
independent predictor of risk of recurrence or death. The
negative prognostic value of exon 11 mutations was signif-
icant in untreated patients but not in the smaller group
receiving adjuvant or neo-adjuvant treatment. This may
be attributable to the high responsiveness of KIT exon 11-
mutated patients to imatinib.15
Previous studies have reported similar results for GISTs
of different sites, demonstrating that tumors with KIT exon
11 deletions are clinically more aggressive than those with
exon 11 point mutations. In particular, KIT deletions
affecting codons 557 or 558 have been associated with met-
astatic behavior, a high risk of relapse and shorter RFS and
OS with respect to other KIT exon 11 mutations or deletions
involving other codons.14,19,21e25,27,31,33
The higher risk of recurrence or death in patients with
GISTs showing abnormalities in exon 11 codons 557 or
558 would seem to be due to the important role of the
amino acids encoded by these two codons in KIT protein
function. A number of juxtamembrane residues are needed
to inhibit spontaneous KIT phosphorylation. In fact, an in-
crease in phosphorylation could be due to the removal of
the side chain of codons 553, 557, 559 or 560. In particular,
codon 557 encodes for a juxtamembrane residue respon-
sible for preventing spontaneous receptor phosphorylation
and activation. Trp-557-Ala leads to a substantial increase
in receptor phosphorylation. Similarly, Lys-558-Pro causes
spontaneous receptor phosphorylation which may be higher
than stem cell factor-induced wild-type receptor phosphor-
ylation. These mutation-induced conformational receptorchanges lose their inhibitory control of the kinase activity
of the ligand-unoccupied KIT receptor. Furthermore, co-
dons 557 and/or 558 deletions may lead to a perturbation
of kinase autoinhibition via the disruption of protein
conformation.23,34
A recent study identified three molecular risk subgroups
on the basis of different KIT, PDGFRA and BRAF muta-
tions at different exons.27 We were not able to verify this
biological classification because our case series was smaller
and also because some alterations were either detected in
only a few patients or not at all. We did not find mutations
in BRAF gene, in agreement with some studies.28,35
Conversely, a number of studies reported a 4e13% fre-
quency of BRAF mutation (V600E) in KIT and PDGFRA
wt GIST patients,8,9,27 the majority of which were of small
bowel origin, suggesting a strong predisposition for tumors
arising in this part of the gastrointestinal tract.8,9 This may
explain the absence of BRAF mutations in our case series
composed entirely of gastric GISTs.
As far as we know, this is the largest study conducted to
date on gastric GISTs characterized at molecular level. Its
main weakness stems from its retrospective nature, with
the obvious difficulty in collecting clinical information
and the consequent limitation in the number of patients
for whom the analysis of prognosis was possible. Moreover,
despite the known disadvantages of a composite endpoint,
we decided to use it in our study because of the potential
underreporting of disease recurrences related to the non ho-
mogeneous availability of follow up in the different centers
involved in the study. Finally, findings from the analysis of
the treated group should be interpreted with caution due to
the consequently smaller sample size on which estimated
hazard ratios were based.
In conclusion, we found that KIT mutations, especially
deletions involving exon 11 codons 557, 558 or 559, in
gastric GISTs were associated with a more aggressive
phenotype and a higher risk of recurrence or death. This
finding underlines the need for a more specific and broader
1213L. Capelli et al. / EJSO 42 (2016) 1206e1214molecular analysis for GIST patients to identify those at
higher risk of relapse who could benefit from adjuvant
treatment with imatinib. Furthermore, our data could be
used to improve the present classification system by team-
ing up specific molecular alterations with currently used
pathological criteria.
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